Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-dose olanzapine for treatment-resistant schizophrenia.

The Journal of clinical psychiatry - 1 Feb 2008

Roth Bryan L

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Benzodiazepines
Share to Clozapine
Share to Drug Resistance

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Olanzapine

Share to Randomized Controlled Trials as Topic

Share to Receptor, Serotonin, 5-HT2A

Share to Schizophrenia

Source

Identifiers

PMID: 18363451
DOI: 10.4088/jcp.v69n0201

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-dose olanzapine for treatment-resistant schizophrenia.PMID 18363451Read ↗

Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients.Semantic proximity Read ↗

Drawbacks of Olanzapine Therapy: An Emphasis on Its Metabolic Effects and DiscontinuationSemantic proximity Read ↗

Amisulpride Augmentation Therapy Improves Cognitive Performance and Psychopathology in Clozapine-resistant Treatment-refractory Schizophrenia (CTRS): a 12-week Randomized, Double-blind, Placebo-controlled TrialSemantic proximity Read ↗

Antipsychotic Selection in Combination with Electroconvulsive Therapy for Acute Schizophrenia: Differential Efficacy and Safety Profiles from a Real World StudySemantic proximity Read ↗

Effect of Genetic Variants, Gender, and Co-treatment on Olanzapine Plasma Concentration in Chinese patients with schizophreniaSemantic proximity Read ↗

A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.Semantic proximity Read ↗

Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in SwitzerlandSemantic proximity Read ↗

“Chill Packs” Self-Administered Olanzapine as Psychiatric Harm Reduction for Methamphetamine-Induced Psychosis: A Narrative Review of the Existing Evidence BaseSemantic proximity Read ↗

Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisationSemantic proximity Read ↗

The Clinical Antipsychotic Effect of Recently Developed Antipsychotic Drugs in SchizophreniaSemantic proximity Read ↗

Prescribing trends for the same patients with schizophrenia over 20 yearsSemantic proximity Read ↗

Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.